Desloratadine Teva



This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Desloratadine Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Desloratadine Teva.

This EPAR was last updated on 09/06/2022

Authorisation details

Product details
Desloratadine Teva
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Rhinitis, Allergic, Perennial
  • Rhinitis, Allergic, Seasonal
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva B.V
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Swensweg 5
2031GA Haarlem
The Netherlands

Product information

30/05/2022 Desloratadine Teva - EMEA/H/C/002419 - PSUSA/00000962/202107

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antihistamines for systemic use

Therapeutic indication

Desloratadine Teva is indicated for the relief of symptoms associated with:

  • allergic rhinitis;
  • urticaria.

Assessment history

How useful was this page?

Add your rating
1 rating
1 rating